Cited by 637Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

The DOI matches its Crossref record.

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Open access

Chesi, Marta, Nardini, Elena, Brents, Leslie A., Schröck, Evelin, Ried, Thomas, Kuehl, W. Michael, Bergsagel, P. Leif·1997·Nature Genetics

DOI 10.1038/ng0797-260PMC PMC3901950

Open this paper in CoChat — free account

Abstract

Dysregulation of oncogenes by translocation to the IgH locus (14q32) is a seminal event in the pathogenesis of B-cell tumours. In multiple myeloma (MM), translocations to the IgH locus have been reported at an incidence of 20-60%. For most translocations, the partner chromosome is unknown (14q+); for the others, a diverse array of chromosomal partners have been identified, with 11q13 (cyclin D1) the only chromosome that is frequently involved. Recently, we developed a Southern-blot assay that detects translocation breakpoint fragments in most MM tumours, including those with no translocation detected by conventional karyotyping. In a continuing analysis of translocation in 21 myeloma cell lines and primary tumours, we show that the novel, karyotypically silent translocation t(4;14)(p16.3;q32.3) is present in five lines and at least three of ten primary tumours. The chromosome-4 breakpoints are clustered in a 70-kb region centromeric to the fibroblast growth factor receptor 3 gene (FGFR3), the apparent dysregulated oncogene. Two lines and one primary tumour with this translocation selectively express an FGFR3 allele containing activating mutations identified previously in thanatophoric dwarfism. We propose that after the t(4;14) translocation, somatic mutation during tumour progression frequently generates in FGFR3 protein that is active in the absence of ligand.

Integrity signals

Registry

Crossref · 10.1038/ng0797-260

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No references could be resolved yet.

Research works printed but not linked: 31

Korsmeyer, S.J. Chromosomal translations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol. 10, 785–607 (1992). · DOI
Taniwaki, M. et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84, 2283–2290 (1994). · DOI
Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 82, 41–49 (1995). · DOI
Lai, J.L. et al. Improved cytogenetics in multiple-myeloma—a study of 151 patients including 117 patients at diagnosis. Blood 85, 2490–2497 (1995). · DOI
Chesi, M. et al. Dysregulation of Cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674–681 (1996). · DOI
Bergsagel, P.L. et al. Promiscuous translations into IgH switch regions in multiple myeloma. Proc. Natl. Sci. Acad. USA 93, 13931–13936 (1996). · DOI · Paper page
Baxendale, S. et al. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nature Genet. 4, 181–186 (1993). · DOI
Keegan, K., Johnson, D., William, L.T. & Hayman, M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad Sci. USA 88, 1095–1099(1991). · DOI
Keegan, K., Meyer, S. & Hayman, M.J. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6, 2229–2236 (1991).
Muenke, M. & Schell, U. Fibroblast-growth-factor-receptor mutations in human sketetal disorders. Trends Genet. 11, 308–313 (1995). · DOI
Naski, M.C., Wang, Q., Xu, J. & Ornitz, D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet. 13, 233–237 (1996). · DOI
Webster, M.K., D'Avis, P.Y., Robertson, S.C. & Donoghue, D.J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16, 4081–4087 (1996). · DOI
Webster, M.K. & Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520–527 (1996). · DOI
Rousseau, F. et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism typeI (TD1). Hum. Mol. Genet. 5, 509–512 (1996). · DOI
Francomano, C.A. et al. A new skeletal dysplasia with severe tibial bowing, profound developmental delay and acanthosis nigricans is caused by a Lys 650 Met mutation in fibroblast growth factor receptor 3 (FGFR3). Am. J. Hum. Genet. 59, A25 (1996).
Tavormina, P.L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 9, 321–328 (1995). · DOI
Williams, M.E., Swerdlow, S.H. & Meeker, T.C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7, 1437–1440 (1993).
Tsujimoto, Y. et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315, 340–343 (1985). · DOI
de Boer, C.J. et al. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 53, 4148–4152 (1993).
Mason, I.J. The ins and outs of fibroblast growth factors. Cell 78, 547–552 (1994). · DOI
Su, W.S. et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288–292 (1997). · DOI
Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390–397 (1996). · DOI
Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911–921 (1996). · DOI
Ornitz, D.M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267, 16305–16311 (1992). · DOI
Caligaris-Cappio, F. et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77, 2688–2693 (1991). · DOI
Allouche, M. Basic fibroblast growth factor and hematopoiesis. Leukemia 9, 937–942 (1995).
Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335–342 (1994). · DOI
Johnston, C.L., Cox, H.C., Gomm, J.J. & Coombes, R.C. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. J. Biol. Chem. 270, 30643–30650 (1995). · DOI
Schröck, E. et al. Multicolor spectral karyotyping of human chromosomes. Science 273, 494–497 (1996). · DOI
Kuehl, W.M., Brents, L.A., Chesi, M. & Bergsagel, P.L. Selective expression of one c-myc allele in two human myeloma cell lines. Cancer Res. 56, 4370–4373 (1996).
Davis, L.G., Kuehl, W.M. & Battey, J.F., Methods in Molecular Biology (Appleton & Lange, Norwalk, Connecticut, 1994).

Sorted by citations

Items 101–200 of 590

Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations
Corcoran, M., Mould, S., Orchard, J., Ibbotson, R., Chapman, R., Boright, A. P., Platt, C., Tsui, L.-C., Scherer, S. W., & Oscier, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203033 · Cited by 153
“Dysregulation of oncogenes by translocation to an immunoglobulin heavy or light chain locus is a frequent event in the pathogenesis of B-cell malignancies (Korsmeyer, 1992; Rabbitts 1994; Chesi et al., 1997).”
BackgroundMethod
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
Bernard-Pierrot, I., Brams, A., Dunois‐Lardé, C., Caillault, A., de Medina, S. G. D., Cappellen, D., Graff, G., Thiery, J., Chopin, D., Ricol, D., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi290 · Cited by 150
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma.
Rao, P., Cigudosa, J., Ning, Y.-H., Calasanz, M., Iida, S., Tagawa, S., Michaeli, J., Klein, B., Dalla-Favera, R., Jhanwar, S., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1743 · Cited by 149
Self-citation
New insights into the pathophysiology of multiple myeloma
Seidl, S., Kaufmann, H., & Drach, J. W. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01195-1 · Cited by 134
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
Walker, B. A., Wardell, C. P., Johnson, D. C., Kaiser, M. F., Begum, D. B., Dahir, N. B., Ross, F. M., Davies, F. E., Gonzalez, D., & Morgan, G. J. (2013) · Blood · doi:10.1182/blood-2012-12-471888 · Cited by 166
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma
Preudhomme, C., Roumier, C., Hildebrand, M. P., Dallery-Prudhomme, E., Lantoine, D., Laï, J. L., Daudignon, A., Adenis, C., Bauters, F., Fenaux, P., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203521 · Cited by 135
“3 region, implicating the FGFR3 gene, which was shown to be deregulated by juxtaposition to the IgH gene, in this observation (Chesi et al., 1997).”
Background
Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer
Ricol, D., Cappellen, D., Marjou, A. E., Gil‐Diez‐de‐Medina, S., Girault, J., Yoshida, T., Ferry, G., Tucker, G., Poupon, M., Chopin, D., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203186 · Cited by 143
“In haematopoietic malignancies, translocations involving FGFR1 or FGFR3 have demonstrated that FGF receptors may have oncogenic properties (Chesi et al., 1997; Xiao et al., 1998).”
Background
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D., Hurst, C., & Knowles, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 142
“Around 10–20% of myeloma patients show a t(4;14)(p16;q32) that translocates FGFR3 on chromosome 4 into the IgH locus on chromosome 14, resulting in some cases, in overexpression of FGFR3 (Chesi et al., 1997, 1998; Richelda et al., 1997).”
Background
The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines.
Still, I., Vince, P., & Cowell, J. (1999) · Genomics · doi:10.1006/geno.1999.5829 · Cited by 141
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padró, T., Kropff, M. H., Scheffold, C., Kröger, M., Mesters, R. M., Berdel, W. E., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2907 · Cited by 127
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations
Chng, W., Santana-Davila, R., Wier, S. V. V., Ahmann, G., Jalal, S., Bergsagel, P., Chesi, M., Trendle, M., Jacobus, S., Blood, E., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404172 · Cited by 137
Self-citation
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
Laird, A., & Cherrington, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.51 · Cited by 130
“FGFR-3* Multiple myeloma cells Translocation into IgH locus resulting in overexpression, sometimes followed by activating mutations: multiple myeloma [98-101]”
Background
FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer
Thussbas, C., Nährig, J., Streit, S., Bange, J., Kriner, M., Kates, R. E., Ulm, K., Kiechle, M. B., Hoefler, H., Ullrich, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8587 · Cited by 131
Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Janssen, J., Vaandrager, J., Heuser, T., Jauch, A., Kluin, P., Geelen, E., Bergsagel, P., Kuehl, W., Drexler, H., Otsuki, T., et al. (2000) · Blood · doi:10.1182/blood.v95.8.2691.008k16_2691_2698 · Cited by 135
Self-citation
Genetics of multiple myeloma: another heterogeneity level?
Corre, J., Munshi, N. C., & Avet‐Loiseau, H. (2015) · Blood · doi:10.1182/blood-2014-10-567370 · Cited by 145
Fibroblast growth factor receptors, developmental corruption and malignant disease
Kelleher, F. C., O’Sullivan, H., Smyth, E., McDermott, R., & Viterbo, A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt254 · Cited by 131
Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions
Chang, H., Sloan, S. R., Li, D., & Stewart, A. K. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05199.x · Cited by 124
“…the IgH joint and constant regions (kindly provided by Dr Avet-Loiseau; Avet-Loiseau et al, 1999); a 22-kb FGFR3 segment in a cosmid vector obtained from Dr Bergsagel (Chesi et al, 1997); a P1 clone containing the c-MAF gene (provided by Dr Kuehl; Chesi et al, 1998); c-MYC and Cyclin D1 (Vysis).”
Background
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.
Hayman, S., Bailey, R. J., Jalal, S. M., Ahmann, G., Dispenzieri, A., Gertz, M., Greipp, P., Kyle, R., Lacy, M., Rajkumar, S., et al. (2001) · Blood · doi:10.1182/blood.v98.7.2266 · Cited by 133
Roles of FGF receptors in mammalian development and congenital diseases
Coumoul, X., & Deng, C. (2003) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.10025 · Cited by 121
“Translocation of the immunoglobulin heavy chain locus at chromosome 14q32 close to the FGFR3 gene (50-120 kb centromeric) in myeloma is a common process (Chesi et al., 1997; Richelda et al., 1997).”
Background
Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.
Hart, K. C., Robertson, S. C., & Donoghue, D. J. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.4.931 · Cited by 131
“The activating mutation Lys6503Glu in the activation loop of the FGFR3 kinase domain underlies the lethal human skeletal disorder TDII (reviewed in Webster and Donoghue, 1996) and is also found in patients with multiple myeloma and bladder and cervical carcinomas (Chesi et al., 1997; Richelda et al., 1997; Cappellen e…”
Influential
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Traer, E. A., Martinez, J., Javidi‐Sharifi, N., Agarwal, A., Dunlap, J. B., English, I. A., Kovacsovics, T. J., Tyner, J. W., Wong, M. H., & Druker, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3569 · Cited by 168
“Activation of FGFRs is known to be a driver in numerous malignancies including FGFR1 fusions in 8p myeloproliferative neoplasms (33,34); t(4;14) translocation with FGFR3 overexpression in multiple myeloma (35,36); FGFR3 mutations in bladder carcinoma (37); and both FGFR1 and FGFR3 fusions in glioblastoma (38), to name…”
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
Kalff, A., & Spencer, A. G. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.37 · Cited by 123
Targeting mutant fibroblast growth factor receptors in cancer
Greulich, H. E., & Pollock, P. M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.012 · Cited by 128
“Translocation only roughly correlates with increased FGFR3 protein expression [5, 7], and there is currently insufficient functional data to conclude that translocation-driven increases in wild-”
BackgroundInfluential
Genomics of Multiple Myeloma
Robiou-du-Pont, S., Cleynen, A., Fontan, C., Attal, M., Munshi, N. C., Corre, J., & Avet‐Loiseau, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.6705 · Cited by 109
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
Scuto, A., Krejčı́, P., Popplewell, L. L., Wu, J., wang, Y., Kujawski, M., Kowolik, C. M., Xin, H., Chen, L., Wang, Y., et al. (2010) · Leukemia · doi:10.1038/leu.2010.289 · Cited by 140
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
Stewart, A. K., & Fonseca, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.023 · Cited by 127
A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges
di Martino, E., Tomlinson, D. C., & Knowles, M. A. (2012) · Advances in Urology · doi:10.1155/2012/429213 · Cited by 121
“FGFR3 mutations are frequent in benign skin tumours [43] and have been reported at low frequency in cervical carcinoma [25] and multiple myeloma [44], but are absent in other solid cancers [45, 46], suggesting a tissue-specific role.”
Background
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
Majewski, I. J., Mittempergher, L., Davidson, N., Bosma, A. R., Willems, S. M., Horlings, H. M., de Rink, I., Greger, L., Hooijer, G. K. J., Peters, D. D. G. C., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4209 · Cited by 118
Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations
Agnelli, L., Bicciato, S., Mattioli, M., Fabris, S., Intini, D., Verdelli, D., Baldini, L., Morabito, F., Callea, V., Lombardi, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3870 · Cited by 115
Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias : combination analysis with cDNA expression array and tissue microarray.
Oka, T., Yoshino, T., Hayashi, K., Ohara, N., Nakanishi, T., Yamaai, Y., Hiraki, A., Sogawa, C., Kondo, E., Teramoto, N., et al. (2001) · American Journal of Pathology · doi:10.1016/s0002-9440(10)62535-7 · Cited by 124
RTK mutations and human syndromes
Robertson, S. C., Tynan, J. A., & Donoghue, D. J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02021-7 · Cited by 143
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
Rajkumar, S. V., & Witzig, T. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0188 · Cited by 120
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
Parker, B. C., Engels, M., Annala, M., & Zhang, W. (2013) · The Journal of Pathology · doi:10.1002/path.4297 · Cited by 116
Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
Harding, T. C., Long, L., Palencia, S., Zhang, H., Sadra, A., Hestir, K., Patil, N. S., Levin, A., Hsu, A. W., Charych, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005414 · Cited by 120
Emerging therapeutic targets in bladder cancer
Carneiro, B. A., Meeks, J. J., Kuzel, T. M., Scaranti, M., Abdulkadir, S. A., & Giles, F. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.11.003 · Cited by 132
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L., & Neri, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204465 · Cited by 119
“These ®ndings are similar to those observed in the KMS-11 and OPM-2 cell lines (Chesi et al., 1997; Richelda et al., 1997), but indicate two substantial di erences: KMS-18 prevalently expresses FGFR3-IIIb and harbors a G384D mutation (G382D in FGFR3-IIIc) which, to the best of our knowledge, has…”
BackgroundMethodInfluential
Monoclonal gammopathies of undetermined significance: a review
Kyle, R. A., & Rajkumar, S. V. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00056.x · Cited by 118
Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.
Gabrea, A., Bergsagel, P., Chesi, M., Shou, Y., & Kuehl, W. (1999) · Molecules and Cells · doi:10.1016/s1097-2765(00)80180-x · Cited by 118
“All sequences are in a telomeric to centromeric orientation. detection protocols are described elsewhere (Chesi et al., 1997).”
BackgroundMethodSelf-citation
Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors.
Finch, P., & Rubin, J. (2006) · Journal of the National Cancer Institute · doi:10.1093/jnci/djj228 · Cited by 117
Targeting the fibroblast growth factor receptor family in cancer
Hallinan, N., Finn, S. P., Cuffe, S. D., Rafee, S., O'Byrne, K. J., & Gately, K. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.015 · Cited by 125
The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP
Smedley, D. P. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.4.637 · Cited by 104
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
Tiedemann, R. E., Zhu, Y. X., Schmidt, J. E., Yin, H. H., Shi, C.-X., Que, Q. Q., Basu, G. D., Azorsa, D. O., Perkins, L. M., Braggio, E., et al. (2009) · Blood · doi:10.1182/blood-2009-09-243980 · Cited by 106
Self-citation
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia
Drexler, H. G., & Matsuo, Y. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00195-2 · Cited by 107
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
Sibley, K., Cuthbert-Heavens, D., & Knowles, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204110 · Cited by 113
“In multiple myeloma, Y373C has been identi®ed in the KMS11 cell line (Chesi et al., 1997; Richelda et al., 1997) and K650E/ K650M mutations have been detected in the OPM2 cell line and one primary tumour (Chesi et al., 1998).”
Background
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
Duncan, C. G., Killela, P. J., Payne, C. A., Lampson, B. L., Chen, W., Liu, J., Solomon, D. A., Waldman, T. A., Towers, A. J., Gregory, S. G., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.137 · Cited by 114
Molecular aspects of multiple myeloma
Kastrinakis, N. G., Gorgoulis, V. G., Foukas, P. G., Dimopoulos, M. A., & Kittas, C. (2000) · Annals of Oncology · doi:10.1023/a:1008331714186 · Cited by 69
“[16, 77, 80-83] [16,81,83] [16,81-83,90-92] [81,83,95] [70] [77,81,96] [99] [101] [77] [102]”
Background
Overview of the role of molecular methods in the diagnosis of malignant lymphomas.
Medeiros, L., & Carr, J. (1999) · Archives of Pathology & Laboratory Medicine · doi:10.1043/0003-9985(1999)123 · Cited by 110
Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
Patani, H., Bunney, T., Thiyagarajan, N., Norman, R., Ogg, D., Breed, J., Ashford, P., Potterton, A., Edwards, M., Williams, S. V., et al. (2016) · OncoTarget · doi:10.18632/oncotarget.8132 · Cited by 108
Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping
Sawyer, J. R., Lukacs, J. L., Munshi, N., Desikan, K., Singhal, S., Mehta, J., Siegel, D., Shaughnessy, J., & Barlogie, B. (1998) · Blood · doi:10.1182/blood.v92.11.4269.423k31_4269_4278 · Cited by 108
Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias
Legeai‐Mallet, L., Benoist-Lasselin, C., Münnich, A., & Bonaventure, J. (2003) · Bone · doi:10.1016/j.bone.2003.09.002 · Cited by 107
Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases
Smadja, N. V., Leroux, D., Soulier, J., Dumont, S., Arnould, C., Taviaux, S. A., Taillemite, J. L., & Bastard, C. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10275 · Cited by 97
“However, CC fails to detect cryptic translocations (Chesi et al., 1997; Richelda et al., 1997; Finelli et al., 1999).”
Background
Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B‐cell lymphoma and multiple myeloma
Baccon, P. L., Leroux, D., Dascalescu, C., Duley, S., Marais, D., Esmenjaud, E., Sotto, J., & Callanan, M. B. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1189 · Cited by 91
“These include the fibroblast growth factor receptor FGFR3 and MMSET genes, deregulated by a cryptic t(4; 14)(p16;q32) observed in about 20% of MM (Chesi et al., 1997, 1998), and the IRF4 gene (interferon regulatory factor 4), targeted by a recurring t(6; 14)(p25;q32) (Iida et al., 1997).”
Background
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma
Keats, J. J., Reiman, T., Belch, A. R., & Pilarski, L. M. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600822128 · Cited by 93
“This translocation involves the sub-telomeric regions of chromosome arms 4p and 14q, making it impossible to identify by conventional cytogenetics or spectral karyotyping [5].”
BackgroundMethodInfluential
Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high‐grade soft tissue sarcoma
Morimoto, Y., Ozaki, T., Ouchida, M., Umehara, N., Ohata, N., Yoshida, A., Shimizu, K., & Inoue, H. (2003) · Cancer · doi:10.1002/cncr.11778 · Cited by 102
Absence or low number of telomere repeats at junctions of dicentric chromosomes
Wan, T. S. K., Martens, U. M., Poon, S. S. S., Tsao, S., Ha, S., & Lansdorp, P. M. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199901)24:1 · Cited by 45
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.
Li, Z.-H., Zhu, Y.-X., Plowright, E. E., Bergsagel, P., Chesi, M., Patterson, B., Hawley, T., Hawley, R. G., & Stewart, A. K. (2001) · Blood · doi:10.1182/blood.v97.8.2413 · Cited by 100
Self-citation
Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma
Akechi, T., Okamura, H., Nishiwaki, Y., & Uchitomi, Y. (2001) · Cancer · doi:10.1002/1097-0142(20011115)92:10 · Cited by 119
Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations
Hanamura, I., Iida, S., Akano, Y., Hayami, Y., Kato, M., Miura, K., Harada, S., Banno, S., Wakita, A., Kiyoi, H., et al. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01142.x · Cited by 93
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
Chu, L., Su, M. Y., Maggi, L. B., Lu, L., Mullins, C. D., Crosby, S., Huang, G.-F., Chng, W., Vij, R., & Tomasson, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63051 · Cited by 98
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays
Berchuck, A., Iversen, E. S., Lancaster, J. M., Dressman, H. K., West, M., Nevins, J. R., & Marks, J. R. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.02.005 · Cited by 92
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.
Fonseca, R., Oken, M., & Greipp, P. (2001) · Blood · doi:10.1182/blood.v98.4.1271 · Cited by 97
Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma
Sawyer, J. R., Lukacs, J. L., Thomas, E. L., Swanson, C., Goosen, L. S., Sammartino, G., Gilliland, J. C., Munshi, N., Tricot, G., Shaughnessy, J., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02546.x · Cited by 96
“The molecular cytogenetic techniques of multicolour fluorescence in situ hybridization (M-FISH) and multicolour spectral karyotyping (SKY) can provide significantly more information because they allow the display of each chromosome in a different colour and, thus, make possible the identification of chromosomal bands…”
BackgroundInfluential
Future applications of FGF/FGFR inhibitors in cancer
Ghedini, G. C., Ronca, R., Presta, M., & Giacomini, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1491795 · Cited by 106
“are reported in 70% of non-muscle-invasive and in 20% of invasive bladder tumors [39–41], as well as in cervical [42], multiple myeloma [43,44], spermatocytic seminomas [45,46],”
Background
FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth
Du, X., Wang, Q.-R., Chan, E., Merchant, M. A., Liu, J., French, D. M., Ashkenazi, A., & Qing, J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1329 · Cited by 108
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
Jaksic, W., Trudel, S., Chang, H., Trieu, Y., Qi, X., Mikhael, J., Reece, D., Chen, C., & Stewart, A. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.129 · Cited by 94
Kinases as targets in the treatment of solid tumors
Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K. M., Khan, K., Ahmed, S. S. L., Stebbing, J., & Knippschild, U. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.011 · Cited by 88
Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance.
Chaganti, R. S. K., Nanjangud, G., Schmidt, H., & Teruya-Feldstein, J. (2000) · Seminars in hematology (Print) · doi:10.1016/s0037-1963(00)90019-2 · Cited by 92
Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
Arellano-Rodrigo, E., Álvarez-Larrán, A., Reverter, J., Villamor, N., Colomer, D., & Cervantes, F. (2006) · Haematologica · doi:10.3324/%x · Cited by 304
Role of genetics in prognostication in myeloma.
Avet-Loiseau, H. (2007) · Baillière's Best Practice & Research: Clinical Haematology · doi:10.1016/j.beha.2007.08.005 · Cited by 91
MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor Signaling
Ren, J., Raina, D. B., Chen, W., Li, G., Huang, L. H., & Kufe, D. W. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0204 · Cited by 89
“MUC1-CD(2072) and MUC1-CD(46-72), but not MUC1-CD(1-45), also formed complexes with FGFR3 (Fig.”
BackgroundInfluential
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
Sawyer, J. R., Lukacs, J. L., Munshi, N., Desikan, K., Singhal, S., Mehta, J., Siegel, D., Shaughnessy, J., & Barlogie, B. (1998) · Blood · doi:10.1182/blood.v92.11.4269 · Cited by 90
Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer
Gust, K. M., McConkey, D. J., Awrey, S. J., Hegarty, P. K., Qing, J., Bondaruk, J. E., Ashkenazi, A., Czerniak, B. A., Dinney, C. P., & Black, P. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1150 · Cited by 97
Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma
Zhu, L.-J., Somlo, G., Zhou, B.-S., Shao, J., Bedell, V., Slovak, M., Liu, X.-Y., Luo, J.-H., & Yun, Y. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0330 · Cited by 89
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors
Hafner, C. M., Toll, A., Fernández-Casado, A., Earl, J., Marqués, M., Acquadro, F., Méndez‐Pertuz, M., Urioste, M., Malats, N., Burns, J. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008365107 · Cited by 94
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
Moreau, P., Attal, M., Garban, F., Hulin, C., Facon, T. T. F., Marit, G., Michallet, M., Doyen, C., Leyvraz, S., Mohty, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404832 · Cited by 91
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
Sibley, K., Stern, P., & Knowles, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204543 · Cited by 88
“…of the lethal germline FGFR3 mutations were identi®ed at high frequency in somatic DNA from bladder carcinoma (Capellen et al., 1999; Sibley et al., 2001) and cervical carcinoma (Cappellen et al., 1999) and at a lower frequency in multiple myeloma (Chesi et al., 1997, 1998; Richelda et al., 1997).”
Background
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
Pruneri, G., Fabris, S., Baldini, L., Carboni, N., Zagano, S., Colombi, M., Ciceri, G., Lombardi, L., Rocchi, M., Buffa, R., et al. (2000) · American Journal of Pathology · doi:10.1016/s0002-9440(10)65022-5 · Cited by 88
Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics
Bink, K., Haralambieva, E., Kremer, M., Ott, G., Beham-Schmid, C., de Leval, L. D., Peh, S., Laeng, H., Jütting, U., Hutzler, P., et al. (2008) · Haematologica · doi:10.3324/haematol.12005 · Cited by 87
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
Paterson, J., Li, Z.-H., Wen, X., Masih-Khan, E., Chang, H., Pollett, J. B., Trudel, S., & Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04814.x · Cited by 87
The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies
Ribatti, D., Vacca, A., Rusnati, M., & Presta, M. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.04.011 · Cited by 86
Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma.
Tsou, A., Wu, K.-M., Tsen, T.-Y., Chi, C., Chiu, J., Lui, W., Hu, C.-P., Chang, C.-M., Chou, C. K., & Tsai, S.-F. (1998) · Genomics · doi:10.1006/geno.1998.5338 · Cited by 82
Aberrant cytokine signaling in leukemia
Etten, R. A. V. (2007) · Oncogene · doi:10.1038/sj.onc.1210758 · Cited by 108
“A related receptor TK, FGFR3, is mutated and overexpressed in multiple myeloma with t(4;14) (Chesi et al., 1997).”
Background
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Szymczyk, J., Służalska, K. D., Materla, I., Opaliński, Ł., Otlewski, J., & Zakrzewska, M. (2021) · Cancers · doi:10.3390/cancers13225796 · Cited by 92
The NF-κB Activating Pathways in Multiple Myeloma
Roy, P., Sarkar, U. A., & Basak, S. (2018) · Biomedicines · doi:10.3390/biomedicines6020059 · Cited by 85
Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.
Hervé, A., Florence, M., Philippe, M., Michel, A., Thierry, F., Kenneth, A., Jean-Luc, H., Nikhil, M., & Stéphane, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8435 · Cited by 79
Emerging therapies for multiple myeloma
Podar, K., Tai, Y., Hideshima, T., Vallet, S., Richardson, P. G. G., & Anderson, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802676278 · Cited by 59
“For example, MM cells with t(14;16) translocation overexpress the transcription factor MAF [104,105] , which not only transactivates the cyclin D2 promoter, but also upregulates β 7-integrin expression and thereby enhances MM cell adhesion to BMSCs [92] .”
Background
Interaction of Fibroblast Growth Factor Receptor 3 and the Adapter Protein SH2-B
Kong, M., Wang, C. S., & Donoghue, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m102777200 · Cited by 79
Blocking the FGF/FGFR system as a two-compartment antiangiogenic/antitumor approach in cancer therapy
Giacomini, A., Chiodelli, P., Matarazzo, S., Rusnati, M., Presta, M., & Ronca, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.024 · Cited by 89
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.
Chang, H., Stewart, A., Qi, X., Li, Z.-H., Yi, Q.-L., & Trudel, S. (2005) · Blood · doi:10.1182/blood-2005-01-0033 · Cited by 78
Chromosomal translocations involved in non-Hodgkin lymphomas.
Vega, F., & Medeiros, L. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.1043/1543-2165(2003)127 · Cited by 78
AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells
Frost, P., Shi, Y., Hoang, B. Q., & Lichtenstein, A. K. (2006) · Oncogene · doi:10.1038/sj.onc.1210019 · Cited by 72
“These angiogenic cytokines overexpressed in myeloma include vascular endothelial growth factor (VEGF) (Bellamy et al., 1999), basic fibroblast growth factor (Chesi et al., 1997) and hepatocyte growth factor (HGF) (Sezer et al., 2001).”
Background
Analysis of PTEN deletions and mutations in multiple myeloma
Chang, H., Xiao, Q., Claudio, J. O., Zhuang, L., Patterson, B. J., & Stewart, A. K. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.07.008 · Cited by 69
Syndecan-1 in B lymphoid malignancies
Sanderson, R. D., & Børset, M. (2002) · Annals of Hematology · doi:10.1007/s00277-002-0437-8 · Cited by 74
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A., & Neri, A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02957.x · Cited by 76
“3 (Chesi et al, 1997, 1998; Richelda et al, 1997).”
Background
From the bench to the bedside: emerging new treatments in multiple myeloma
Mitsiades, C., Hayden, P., Anderson, K., & Richardson, P. (2007) · Targeted oncology · doi:10.1007/s11523-007-0072-3 · Cited by 75
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Dimopoulos, M. A., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117077 · Cited by 72
Origin and Pathogenesis of B Cell Lymphomas
Seifert, M., Scholtysik, R., & Küppers, R. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-269-8_1 · Cited by 86
The Pleiotropic Effects of Fibroblast Growth Factor Receptors in Mammalian Development.
McIntosh, I., Bellus, G. A., & Jabs, E. W. (2000) · Cell Structure and Function · doi:10.1247/csf.25.85 · Cited by 74
“3 that were approximately 50 to 120 kb centromeric of the FGFR3 gene (Chesi et al., 1997; Richelda et al., 1997).”
Background
Controlling Destiny through Chemistry: Small-Molecule Regulators of Cell Fate
Firestone, A. J., & Chen, J. (2009) · ACS Chemical Biology · doi:10.1021/cb900249y · Cited by 71

Authors: Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L.
Affiliations: National Institutes of Health (US)
Cornell University (US)
Corresponding author: Kuehl, W. Michael
ORCID: Chesi, Marta
Schröck, Evelin
Ried, Thomas
Bergsagel, P. Leif
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1997-07
Volume: 16
Issue: 3
Pages: 260-264
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0797-260
PMC: PMC3901950
OpenAlex: W2054290966
Cited by: 637
References: 0
Citations by year: 2026: 4 · 2025: 3 · 2024: 13 · 2023: 14 · 2022: 11 · 2021: 11 · 2020: 14 · 2019: 16 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 15 · 2014: 23 · 2013: 21 · 2012: 26
FWCI: 17.29
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K01CA074265)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords: multiple myeloma, FGFR3, activating mutations, somatic mutations, myeloma cell lines, thanatophoric dwarfism
MeSH terms: Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Humans, Karyotyping, Molecular Sequence Data, Multiple Myeloma, Mutation, Oncogenes, Protein-Tyrosine Kinases, RNA, Messenger, Translocation, Genetic, Tumor Cells, Cultured, Blotting, Southern, Immunoblotting, Blotting, Northern, DNA Probes, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Receptors, Fibroblast Growth Factor, Receptor, Fibroblast Growth Factor, Type 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks